(0.75%) 5 120.50 points
(0.12%) 38 333 points
(1.05%) 17 752 points
(0.72%) $84.17
(-2.63%) $1.595
(0.32%) $2 350.10
(0.99%) $27.63
(1.01%) $929.80
(0.03%) $0.932
(0.13%) $10.97
(0.08%) $0.800
(-0.22%) $91.96
Live Chart Being Loaded With Signals
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders...
Stats | |
---|---|
Today's Volume | 37 140.00 |
Average Volume | 136 523 |
Market Cap | 6 539.16B |
EPS | KRW0 ( 2024-03-17 ) |
Next earnings date | ( KRW46.28 ) 2024-05-12 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW83.11 (0.10%) |
Volume Correlation
SK Biopharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
SK Biopharmaceuticals Correlation - Currency/Commodity
SK Biopharmaceuticals Financials
Annual | 2023 |
Revenue: | KRW354.89B |
Gross Profit: | KRW308.37B (86.89 %) |
EPS: | KRW-419.89 |
Q4 | 2023 |
Revenue: | KRW126.76B |
Gross Profit: | KRW109.46B (86.35 %) |
EPS: | KRW86.32 |
Q3 | 2023 |
Revenue: | KRW90.34B |
Gross Profit: | KRW83.54B (92.48 %) |
EPS: | KRW-177.90 |
Q2 | 2023 |
Revenue: | KRW77.01B |
Gross Profit: | KRW67.64B (87.83 %) |
EPS: | KRW-298.06 |
Financial Reports:
No articles found.
SK Biopharmaceuticals
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators